Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies

Trial Profile

Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications CNS cancer; Ependymoma; Glioma; Medulloblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate 908
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 30 May 2017 Planned End Date changed from 5 May 2021 to 15 Jun 2021.
    • 30 May 2017 Planned primary completion date changed from 4 May 2021 to 14 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top